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Minute Virus of Mice (MVM) shares inherent oncotropic properties with other members of the genus Parvovirus. Two elements responsible, at
least in part, for this oncoselectivity have been mapped to an Ets1 binding site adjacent to the P4 TATA box of the initiating promoter, P4, and to a
more distal cyclic AMP responsive element (CRE), located within the telomeric hairpin stem. Here the CRE overlaps one half-site for the binding
of parvoviral initiation factor (PIF), which is essential for viral DNA replication. We used a degenerate oligonucleotide selection approach to show
that CRE binding protein (CREB) selects the sequence ACGTCAC within this context, rather than its more generally accepted palindromic
TGACGTCA recognition site. We have developed strategies for manipulating these sequences directly within the left-end palindrome of the MVM
infectious clone and used them to clone mutants whose CRE either matches the symmetric consensus sequence or is scrambled, or in which the
PIF binding site is incrementally weakened with respect to the CRE. The panel of mutants were tested for fitness relative to wildtype in normal
murine fibroblasts A9 or transformed human fibroblasts 324 K, through multiple rounds of growth in co-infected cultures, using a differential real-
time quantitative PCR assay. We confirmed that inactivating the CRE substantially abrogates oncoselectivity, but found that improving its fit to the
palindromic consensus is somewhat debilitating in either cell type. We also confirmed that reducing the PIF half-site spacing by one basepair
enhances oncoselectivity, but found that a further basepair deletion significantly reduces this effect.
© 2006 Elsevier Inc. All rights reserved.Keywords: Parvovirus; Oncoselectivity; Cyclic AMP response element; Mutagenesis; Initiating promoter; Virus fitnessIntroduction
The Parvoviridae are a family of small (20–25 nm),
icosahedral, non-enveloped viruses, unique in that they package
a linear single-stranded DNA genome. Several members of the
genus Parvovirus, such as Minute Virus of Mice (MVM), LuIII
and H-1, are known to be inherently oncoselective, demonstrat-
ing enhanced fitness and toxicity in many transformed human
cell types, compared to their normal counterparts, under the
same growth conditions in vitro (Rommelaere and Cornelis,⁎ Corresponding author. Department of Laboratory Medicine, Yale University
Medical School, 333 Cedar Street, New Haven, CT 067510, USA. Fax: +1 203
688 7340.
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doi:10.1016/j.virol.2006.11.0061991; Legrand et al., 1992; Deleu et al., 1999; Cornelis et al.,
2005). In vivo, wildtype parvovirus infection can suppress the
development of certain tumors, for example, H1 suppression of
HeLa tumor growth in SCID mice (Rommelaere and Cornelis,
1991; Faisst et al., 1998; Cornelis et al., 2005). These viruses
have additional qualities that make them promising for
development into useful oncotherapeutic agents, including
their low toxicity in humans and their small size, which
would facilitate spread within a tumor (Rommelaere and
Cornelis, 1991; Dupressoir et al., 1989; Cornelis et al., 2005).
The principal advantage of replication competent oncotropic
viruses is their ability to effectively amplify their own ‘dose’
locally at the targeted therapeutic site through efficient viral
replication in cancerous cells, potentially killing every cell
within an infected tumor mass. In order for such viruses to be
both efficacious and safe, they must simultaneously show little
proclivity for killing normal host cells; that is, they must exhibit
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major determinant of successful virotherapy, modifications to a
virus being developed for oncolytic therapy are often designed
to enhance this selectivity (e.g., Bischoff et al., 1996; Rodriguez
et al., 1997; Hemminki et al., 2001; Everts and van der Poel,
2005). One major determinant of parvoviral oncoselectivity is
the initiating viral P4 promoter. P4 drives expression of the non-
structural protein, NS1 and NS2, which play multiple essential
roles in the viral life cycle, and this promoter has been shown to
be upregulated in ras-transformed rat fibroblasts (Spegelaere
et al., 1991). Transient expression analysis of P4-driven repor-
ter constructs has identified the promoter-distal cyclic AMP-
Response Element (CRE) and the promoter-proximal Ets1
Binding Site (EBS), diagrammed in Fig. 1, as equivalent contri-
butors to the oncoselectivity of P4 in such ras-transformed rat
fibroblasts (Perros et al., 1995; Fuks et al., 1996).
Accordingly, the P4 promoter has become a favored target in
attempts to develop safe, targeted and effective replication-
competent oncolytic parvoviral therapeutic agents. For exam-
ple, Malerba and colleagues (2003) modified the proximal
region of P4 to include binding sites for Tcf, a transcription
factor upregulated by wnt signaling, and showed that this
selectively upregulated P4 activity and viral growth in cells with
active wnt signaling, a feature common in colon cancer.
Unfortunately, although this manipulation rendered both P4
promoter and P4-mutant virus Tcf-responsive, the majority of
colon cancer cells tested remained poorly permissive to viral
growth (Malerba et al., 2006).
An alternative approach has been to modify the existing
transcription factor binding sites within the viral P4 promoter.
We previously reported the effects of mutations introduced into
the distal region of MVM P4 that were designed to coordinately
influence the binding of the cellular protein complex parvoviral
initiation factor (PIF) and other cellular transcription factors that
recognize the viral CRE (Burnett and Tattersall, 2003). PIF is a
heterodimeric transcription factor that recognizes two CpG-
containing tetranucleotide half-sites within the left-end hairpin
stem (Christensen et al., 1997b), one of which overlaps the viral
CRE (Fig. 1). When one of these half-sites was eliminated from
the infectious clone without mutating the CRE, NS1 expression
48 h post-transfection was comparable to wildtype in both A9
and 324 K cells, whereas genomic replication was blocked at
the dimer intermediate, and progeny virion production wasFig. 1. The left-hand end of MVM in hairpin configuration. The left-hand telomeric
features adjacent binding sites for cellular transcription factors E2F, Ets1 and Sp1
immediately proximal to the unpaired GAA-GA ‘bubble’ sequences. The P4-distal re
recognize cellular PIF. An extrahelical thymidine lies immediately distal to the CREcompletely abrogated, characterizing PIF binding as substan-
tially more critical for replication than for P4 promoter activity
(Burnett and Tattersall, 2003).
Significantly, the spacing between PIF half-sites is flexible
(Christensen et al., 1999). Analysis using a degenerate
oligonucleotide selection procedure allowed derivation of a
consensus PIF recognition sequence, ACGPy N1–N9 PuCGPy,
which describes the majority of the binding sites selected by PIF
complexes (Burnett et al., 2001). Furthermore, in vitro off-rate
determinations suggested that a spacing of 6 basepairs between
the two half-site (or 8 between the two CpG dinucleotides) was
optimal, with the affinity falling off by about 25% of maximum
for each basepair added or subtracted from the optimum
(Burnett et al., 2001). Thus, it appears that the spacing of 5
basepairs between half-sites found in the wildtype MVM left-
end is significantly sub-optimal for PIF binding.
Clearly, PIF's potential ability to bind a wide range of
differently spaced, and somewhat degenerate half-sites, presents
some unique possibilities for the accommodation of other
binding site specificities overlapping the PIF binding region.
Thus, reducing the spacing between PIF half-sites, in the
context of the viral left telomere, might alter the phenotype of
the virus by lowering the avidity of PIF binding, allowing
greater occupancy of the CRE by other cellular transcription
factors, such as members of the CREB (cAMP-responsive
element binding) protein and ATF (activated transcription
factor) family. The CREB protein binding sequence has
generally been accepted, in the literature, as the palindrome
TGACGTCA (Montminy et al., 1986; Iguchi-Ariga and
Schaffner, 1989), but this factor is known to be involved in
the transcriptional upregulation of the retinoblastoma gene
promoter, by binding to the asymmetric sequence ACGTCAC
(Sakai et al., 1991; Gill et al., 1994). The MVM left-hand origin
site also contains the sequence ACGTCAC and binds purified
recombinant CREB and ATF1 directly and sequesters ATF/
CREB family members when incubated in cell extracts (Perros
et al., 1995; Christensen et al., 1997a; Burnett, 2002). This site
is also known to be involved in the basal activity of the P4
promoter and to contribute to its ras transformation-associated
stimulation (Perros et al., 1995).
Because the CRE appears to be a significant regulator of
viral oncoselectivity, we originally generated a mutant, no-cre,
in which the wildtype sequence and spacing of the PIF half-siteshairpin lies immediately adjacent to the P4 promoter. The P4 proximal region
. A binding site for viral NS1 sits between the proximal and distal regions,
gion features a CRE that overlaps one of two ACGT half-sites that coordinately
.
Fig. 2. Determination of the preferred CREB binding site. Sequences generated
after four rounds of EMSA selection using recombinant CREB are shown as a
frequency diagram derived from the sequences of 11 independent PCR products.
The “anchored” CpG dinucleotide is located in the fourth and fifth box from the
left. The 7 additional degenerate positions contained approximately 25% of each
base and were omitted from the figure for simplicity.
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was scrambled. This manipulation caused the virus to grow
slightly less well in untransformed A9 cells, while rendering it
almost incapable of growth in SV40-transformed 324 K cells
(Burnett and Tattersall, 2003), thus effectively inverting the
oncoselective phenotype. Since the CRE on the outboard arm of
the extended viral telomere deviates at one out of eight
nucleotides from the accepted symmetric CRE DNA binding
sequence, its importance to viral growth in transformed cells
suggested that altering its sequence to match the symmetric
consensus exactly, in the context of wildtype PIF spacing, might
offer another means of enhancing oncoselectivity.
Conversely, the mutant 4-between, in which one of the
basepairs between the PIF half-sites had been deleted in the
hope that this would enhance CRE usage, was indeed observed
to be more oncoselective than wildtype, by virtue of having
enhanced fitness in transformed cells and impaired fitness in
non-transformed cells (Burnett and Tattersall, 2003). This
suggested the possibility that further reduction in PIF half-site
spacing might incrementally enhance oncoselectivity by giving
even greater advantage to factors binding at the CRE.
In this paper, we describe refinement of the reverse genetics
of parvoviral hairpin telomeres and an improved differential
viral fitness assay based on real-time Polymerase Chain
Reaction (PCR). Using these new tools, we have generated
and characterized additional mutants designed to explore further
the significance of the viral CRE in parvoviral oncoselectivity.
Results
Analysis of the viral CRE by a degenerate oligonucleotide
selection procedure
In order to better define the sequence within the viral CRE
that is important for binding members of the CREB/ATF family,
we used four cycles of selection from a pool of degenerate
duplex oligonucleotides to determine the preferred binding
sequence for recombinant human CREB-327 protein. For this
analysis, the target oligonucleotides were created such that a
single, constant CpG dinucleotide is “anchored” in an 18
nucleotide region of degeneracy, bordered by two constant
primer regions that do not contain CpG in their sequences. As
for previous studies on the PIF binding site (Burnett et al.,
2001), the anchored CpG acts as the core element of the CRE,
providing a reference point from which the selected sequences
were interpreted. At the start of the selection experiment, the
oligonucleotide pool contained approximately 3,300 copies of
every possible combination of bases in the degenerate region
and was incubated with the purified recombinant CREB
polypeptide at a molar ratio of 1:500 (protein to DNA).
Oligonucleotides bound by protein were separated from the
unbound by EMSA, and PCR used to amplify the selected
oligonucleotides, regenerating the pool for the next round of
selection or for analysis. Following four rounds of gel selection,
eleven individual products were cloned from the selected
population and sequenced, as described previously (Burnett et
al., 2001). Results are shown as a frequency diagram in Fig. 2.In this diagram, each nucleotide is represented by a letter that is
proportional in size to the frequency with which that nucleotide
is found at that position in the population of sequences. Thus, an
“anchored” CpG dinucleotide in the degenerate oligonucleotide
pool, in conjunction with four rounds of mobility shift selection,
was sufficient to identify the preferred binding sequence for
recombinant CREB as ACGTCAC, which exactly matches the
putative CRE present in the MVM left-hand end.
Cloning palindromic left-hand ends from replicative forms
In order to explore the sequence requirements within the
CRE, and its functional relationship to the overlapping PIF
binding site, in the context of viral infection, we sought to
improve the techniques for performing reverse genetics in this
region. Stocks of left-hand end mutant MVM viruses 3-between,
4-between and no-cre, diagrammed in Fig. 3, had been generated
as described previously (Burnett and Tattersall, 2003) but did not
exist as infectious plasmids, in which form they could be better
preserved and genetically manipulated. The parvoviral left-hand
end, however, cannot be cloned directly from the hairpin
configuration found in encapsidated viral genomes but must be
cloned in its extended conformation, as found in RF isolated
from infected cells (Fig. 4A). The extended left-end of monomer
RF is difficult to clone directly because viral NS1 is covalently
attached to its 5′ terminal nucleotide, and because it is
palindromic, so that most restriction enzymes that cut on one
side of the axis of symmetry also cut on the other. These two
arms of the palindrome are not perfectly symmetrical, however,
owing to the unpaired ‘bubble’ nucleotides and extrahelical
thymidine in the hairpin stem. Fortuitously this asymmetry,
which is vital to genomic replication (Cotmore and Tattersall,
2006; Burnett et al., 2006), also generates a single BsaAI
restriction site on the outboard arm of the palindrome. The
presence of this BsaAI site makes it possible to capture the left-
end of monomer RF, including all sequences inboard of this
site, in the plasmid pCATCH, constructed, as described in the
Materials and methods section, to contain an unique BsaAI site
in the outboard arm of the left-end terminal palindrome.
Despite the fact that nucleotide changes in 3-between and
no-cre each affected this BsaAI site, in both cases its canonical
YAC/GTR recognition sequence was maintained. We were
therefore able to clone each of the previously described mutant
left-ends from viral RF and reconstruct them back into
infectious plasmids by reintroducing the BsrGI to XbaI
Fig. 3. Sequences of wildtype and mutant P4-distal regions. In no-cre, the PIF
half-site spacing is unaltered but the intervening asymmetric CRE sequence is
scrambled. In symmetric-cre, a substitution mutation (in bold) creates a
palindromic TGACGTCA CRE site, in conjunction with the extrahelical T on
the upper strand. In 4-between and 3-between, the number of nucleotides
between PIF half-sites is reduced but the asymmetric CRE sequence is unaltered.
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subsequently confirmed by DNA sequencing and mutant virus
stocks re-derived by transfection.
Direct cloning of left-end telomeres into infectious plasmids
In our previous method for constructing P4-distal mutants,
these were generated as infectious, but unclonable, ligation
products (Burnett and Tattersall, 2003). In an improved strategy,
described in the Materials and methods section, we again took
advantage of the asymmetric BsaAI site within the left-endpalindrome. Instead of generating mutant left-hand ends in the
hairpin configuration as before, in the current approach they are
constructed in their left-end extended configuration by cloning
directly into pCLIP-distal, a derivative of the infectious plas-
mid, without having to first generate mutant virus. Details of the
extended left-end of the infectious plasmid pdBMVp are shown
in the upper panel of Fig. 4B. In order to facilitate the cloning of
synthetic left-ends, a PCR product generated from bacterioph-
age ΦX174 genomic DNA, with terminal SapI sites, was
“blunt-end” cloned into pCATCH between the BsaAI and PmeI
sites. This was then reconstituted with the BsrGI to XbaI
fragment from pdBMVp, resulting in the non-infectious viral
clone pCLIP-distal (Fig. 4B, middle section). SapI sites direct
cleavage outside of their directional (i.e., non-palindromic)
recognition sequence; therefore, SapI cleaves pCLIP-distal just
outside of the insert – within MVM genomic sequence – as
indicated in the middle section of Fig. 4B. The recipient
construct, with the 1.4-kb ΦX174 SapI fragment cleaved out, is
easily separated from its parental plasmid and bears unique 3′
overhangs, three nucleotides long, at each end. These allow
straightforward directional cloning of two annealed, comple-
mentary, mutant left-end oligonucleotides, as shown in the
lower section of Fig. 4B, and can be used to directly embed
mutant versions of the viral hairpin in the infectious clone.
When basepaired in the extended form of the left-hand end,
the extrahelical T present in the hairpin initiates the 8 basepair
sequence TCACGTCA. This is very similar to the palindromic
sequence, TGACGTCA, which, as discussed previously, has
generally been accepted as the consensus binding site for
CREB/ATF family members (Montminy et al., 1986; Iguchi-
Ariga and Schaffner, 1989; Hai and Hartman, 2001). We have
previously reported (Burnett and Tattersall, 2003) that the
extrahelical T contributes to the oncoselectivity of wildtype
CRE, since the P4 promoter-distal mutant no-T, in which this
nucleotide is deleted, is more impaired for growth in
transformed cells than in normal cells. In order to ask whether
substitution of the asymmetric CRE with the symmetric site
might afford the virus an oncoselective advantage, we used the
pCLIP-distal cloning strategy to generate symmetric-cre by
incorporating a single C:G to G:C transversion into the hairpin
stem, as shown in Fig. 3. The mutation in this plasmid was
authenticated by DNA sequencing, and infectious virus
recovered by transfection into 324 K cells. Mutant virus stocks
were then generated and compared with the other mutants, in
both A9 and 324 K cells, for infection initiation efficiency and
for fitness by direct competition against the wildtype.
Characterization of mutant viruses by infection initiation
efficiency assay
The relative efficiencies of parvoviral infection can be
assessed by measuring the percentage of cells positive for viral
NS1 antigen at 24 h post-infection, over a range of input
genomes per cell, under conditions that limit infection to a single
cycle of growth. Purified, plasmid transfection-derived stocks
of wildtype, no-cre, symmetric-cre, 4-between and 3-between
viruses were used to evaluate the efficiency of initiation of
Fig. 4. Arrangement of the extended left-hand end in monomer RF and pCLIP. The top of panel A shows 5 kb monomer RF as generated during genomic replication, in
which the extended and basepaired hairpin loops are represented by shaded rectangles. The locations of the BsaAI, BsrGI, HpaI and XbaI sites mentioned in the text
are indicated. The lower section shows sequence detail of the 1,223 basepair BsaAI to BsrGI fragment that incorporates most of both the outboard and inboard arms of
the terminal palindrome. The upper section of panel B diagrams the extended left-end telomere within the infectious plasmid pdBMVp. In pCLIP-distal, a 1.4-kb
ΦX174 ‘filler’ DNA sequence, engineered to include terminal SapI sites, is inserted between the BsaAI and PmeI sites, as shown in the middle section. SapI cleaves
outside of the insert into genomic sequence, allowing the direct insertion of annealed oligonucleotides incorporating any desired mutation(s), as shown in the lower
section.
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cells, as shown in Fig. 5. The relative initiation efficiencies
observed for wildtype and the mutants no-cre and 4-between
are comparable to those previously published (Burnett and
Tattersall, 2003). Specifically, 4-between initiates with wildtype
or near-wildtype efficiency in A9 and 324 K cultures, whereas
no-cre initiates less efficiently than wildtype in A9 and
dramatically less efficiently in 324 K cells. Of the new mutants,
symmetric-cre initiated with wildtype efficiency in both cell
lines, while 3-between was somewhat impaired in both.
Differential quantitation of viral genomes using real-time PCR
In order to assess the fitness of each mutant, relative to
wildtype, competition experiments were performed over multi-
ple rounds of infection, similar to those in the original analysis
(Burnett and Tattersall, 2003), which used Southern blotting
methodology. Since this approach was very labor intensive and
time consuming, we sought to replace it with a differential real-time quantitative (Q) PCR assay, using the TaqMan® detection
system. For this, a novel phenocopy of wildtype MVMp,
dubbed ‘variant’, was constructed, which contained a string of
nucleotide substitutions at the third, or “wobble”, position of
nine consecutive codons in the VP gene, as illustrated in the
upper panel of Fig. 6. Such changes should allow differential
binding of specific fluorescent probes but should not affect viral
fitness since they do not alter the amino acid sequence of the
structural polypeptide. As expected, the initiation efficiency of
the ‘variant’ version of wildtype virus, recovered from this
construct by transfection, was indistinguishable from that of
‘standard’ wildtype, as shown in Fig. 5.
Two separate probes were designed, specific for this DNA
sequence in ‘variant’ or ‘standard’ genomes (Fig. 6, upper
panel), and labeled with either VIC or FAM fluorophores,
respectively. Outside primers within common sequence flank-
ing the genome tags were used to amplify this region with equal
efficiency from ‘standard’ or ‘variant’ viruses. In TaqMan PCR,
the cycle at which detectable fluorescence crosses a defined
Fig. 5. Relative efficiency of initiation of viral infection. Infection initiation
dose–response curves were determined by measuring the percentage of NS1-
positive nuclei 24 h post-infection in rapidly dividing A9 (panel A) or 324 K
(panel B) cells, over a 625-fold range of input multiplicities, between 40 and
25,000 genomes per cell. Each data point is the average percentage of NS1-
positive cells from multiple randomly chosen fields at a magnification of ×200
(approximately 100 cells/field), and error bars indicate one standard deviation
from the mean. □, ‘variant’ wildtype; ♦, ‘standard’ wildtype; ●, no-cre; ○,
symmetric-CRE; ◊, 4-between; ■, 3-between.
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tion of target sequence. Ten-fold serial dilutions of plasmids,
containing either the ‘standard’ or the ‘variant’ genome, were
made over a wide range of genome concentrations and
subjected to QPCR in order to establish the linear range of
the assay. For both ‘standard’ and ‘variant’ plasmids, log10 input
genomes per reaction correlated in a highly linear inversefashion with Ct values, between 102 through 107 genomes per
reaction (Pearson's r=−0.9997 and r=−0.9989, respectively).
With subsequent runs of the assay, plasmid standards were
measured at 103 through 107 genomes per reaction to generate a
standard curve for calculating the number of genomes per
reaction unknowns, based on their Ct values. To explore the
utility of the plasmid standard curve for quantifying encapsi-
dated viral genomes, purified stocks of viruses with either
‘standard’ and ‘variant’ genomes, titrated by Southern blot,
were subjected to the PCR procedure at dilutions yielding 107,
105 and 103 genomes per reaction. To determine how accurately
‘standard’ and ‘variant’ genomes could be measured simulta-
neously, we tested equimolar mixtures of ‘standard’ and
‘variant’ viruses at 107, 105 and 103 genomes per reaction.
All 30 of these measured values, when plotted with the
appropriate plasmid-generated standard curve, demonstrated a
high degree of linear correlation (r=0.9997 and r=0.9977 for
‘standard’ (FAM) and ‘variant’ (VIC) plots, respectively; Fig. 6,
lower panel). Thus, the plasmid-generated standard curve
allows encapsidated ‘standard’ or ‘variant’ genomes to be
accurately quantified over a wide range of input. The specificity
of the two probes was confirmed in singleplex Q-PCR assays
where 107 ‘standard’ genomes gave no signal with the ‘variant’
probe, and a similar concentration of ‘variant’ genomes re-
mained negative with the ‘standard’ probe (Ct values >45).
Competitive co-infection assayed by real-time Q-PCR to
determine relative fitness
The relative oncoselectivity of each MVMp P4 mutant was
assessed by comparing the results of competition assays in A9
and 324 K cells. Cultures were initially co-infected with inocula
containing equimolar ratios of ‘variant’ wildtype and either
mutant or wildtype virus with the ‘standard’ sequence in the
probe binding region, and allowed to expand for 48 h. Virus was
then harvested from each culture and the numbers of ‘standard’
and ‘variant’ genomes measured, in duplicate, by differential Q-
PCR. Subsequent ‘rounds’ of competition were initiated at 40
genomes per cell, based on these total genome counts. Fig. 7
shows the results, over four rounds of competition, for co-
infection of A9 and 324 K cells with mixtures of ‘variant’
wildtype and ‘standard’ versions of wildtype, no-cre, sym-
metric-cre, 4-between and 3-between. In co-infections of either
A9 or 324 K, the wildtype with the ‘standard’ genome is again
indistinguishable from the ‘variant’ wildtype, as expected.
While the no-cre virus was somewhat out-competed by wild-
type in both cell lines, it was substantially more impaired for
growth in 324 K than in A9 cells, consistent with a significant
role for the CRE in mediating the oncoselectivity of the P4
promoter. Significantly, symmetric-cre was selected against
equally in both cell types, indicating that this mutation does not
provide any improvement in oncoselectivity over wildtype. On
the other hand, while 3-between demonstrates decreased fitness
in both A9 and 324 K, this phenotype is more pronounced in A9,
suggesting that the mutation does confer a slight enhancement in
oncoselectivity. However, this is not as clear a demonstration of
enhanced oncoselectivity as observed for 4-between, which
Fig. 6. Design and validation of differential Q-PCR. The upper panel shows the nine silent mutations engineered into codons 261 to 269 of VP2 in pdBMVp, starting at
nucleotide 3571, that generate pdBMVp-variant, from which ‘variant’ wildtype was recovered. Anti-sense probes specific for ‘standard’ and ‘variant’ DNA sequences
were labeled with FAM and VIC, respectively. The lower panel depicts real-time QPCR measurement of ‘standard’ and ‘variant’ genomes, detected by FAM and VIC
fluorescence, respectively, plotted against input genomes, in a log:log plot. Each graph includes 27 data point representing a plasmid standard curve in duplicate and 15
measurements of encapsidated virus.
Fig. 7. Relative fitness of P4 mutants. The fitness of ‘standard’ versions of wildtype and each of the P4-distal mutants was determined by multiple rounds of
competition against the surrogate ‘variant’ wildtype in A9 (panel A) and 324 K (panel B) co-infected cell cultures. Each bar represents the percentage of viral genomes
represented by the indicated ‘standard’ virus, the remainder being represented by ‘variant’ wildtype, as determined by differential real-time Q-PCR. All initial inocula
(white bars) contained approximately 50% ‘standard’ and 50% ‘variant’ genomes; error bars for the initial inoculum data points represent two standard deviations from
the mean for at least 10 measurements on 5 different days. After each round of competition, harvested virus was assessed for the ratio of ‘standard’ to ‘variant’
genomes; error bars for these data points represent two standard deviations from the mean for two measurements taken on a single day.
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substantially disadvantaged in A9 cultures, suggesting that this
arrangement may be the optimally oncoselective configuration
for this part of P4 promoter. This result differs from our
previously published finding that 4-between was more fit than
wildtype in 324 K. For the current studies, infections were
initiated at a lower multiplicity and harvested at an earlier time
point than previously because we were concerned that trans-
complementation might be skewing the read-out, since a
significant number of cells became co-infected at the higher
multiplicity and longer incubation times used initially. The
differential QPCR assay is more sensitive than the Southern blot
approach used in the original study, making accurate quantita-
tion of differential viral growth possible under these modified
conditions. If this explanation for the different findings is
correct, it would suggest that, under the former conditions,
4-between was complemented in trans by wildtype or wild-
type was inhibited in trans by 4-between. The latter possibility
fits better with the idea that 4-between has a greater affinity for
P4-activating transcription factors and thus may compete
successfully with the wildtype CRE for binding these factors
in co-infected nuclei.
Discussion
While the degenerate oligonucleotide used in the selection
experiments was designed to allow the palindromic sequence
TGACGTCA or the asymmetric sequence ACGTCAC to be
selected with equal efficiency, the latter sequence was clearly
preferred by recombinant human CREB protein, since the two
nucleotides upstream of the ACGT tetrad remained random
across all of the selected sequences. The fact that functional
CREB binding sites in both the MVM P4 and retinoblastoma
gene promoters both match this selection-derived sequence
further indicates that CREB does not require a palindromic
recognition sequence to be able to bind DNA site-specifically
and function as a transcriptional transactivator, suggesting that
the commonly accepted palindromic consensus CRE may
actually represent two overlapping CREB binding sites,
arranged in opposite orientations. The significant disadvantage,
in both normal and transformed cell types, conferred by
changing the outboard MVM left-end CRE to a palindromic
sequence, supports this conclusion and further points to a
possible requirement for directionality of CREB/ATF factor
binding with respect to the downstream P4 promoter.
The sequence ACGTCAC has been shown to bind a variety
of CREB/ATF family proteins present in cell extracts (Perros et
al., 1995; Christensen et al., 1997a). However, the combinations
of the 20 or so members of the ATF/CREB family of bZIP
transcription factors potentially able to bind the MVM CRE as
homodimers or heterodimers are legion. This potential
complexity is further vastly increased by the ability of CREB/
ATF family members to heterodimerize with other bZIP
proteins, including members of the AP-1 and C/EBP families
(Hai and Hartman, 2001). Possibly, the presence of different
combinations of these bZIP dimers at different concentrations or
in different states of activation in transformed cells underlies theoncoselectivity of the CRE. Thus, for example, three cellular
complexes that bound to the MVM CRE were identified in rat
fibroblasts, but in extracts from ras-transformed rat fibroblasts
the least abundant of these became the predominant CRE
binding species (Perros et al., 1995). Subsequent studies
suggested that this complex may be an ATF1/ATF2 heterodimer
(Perros et al., 1999). Significantly, different bZIP dimers have
slightly different binding-site preferences (Hai and Curran,
1991). Thus, altering the sequence of the CRE, rather than or in
addition to altering its availability for binding by altering PIF
site spacing, may enhance its oncoselectivity. However, the
rearrangements introduced in the symmetric-cre virus failed to
achieve this goal. Instead, this mutant is moderately impaired in
both cell lines, showing that the modification did not enhance
oncoselectivity, and that, in fact, the virus benefits from con-
taining an asymmetric CRE.
In this report, we confirm our previous finding (Burnett
and Tattersall, 2003) that reducing the spacing between PIF
half-sites by one basepair, in 4-between, increases the onco-
selectivity of MVM in the A9 versus 324 K cell model. Since
this reduced spacing effectively decreases its affinity for
binding PIF (Burnett et al., 2001), a factor which is absolutely
required for viral genomic replication but contributes mini-
mally to P4 promoter function, it appears likely that the result-
ing enhanced oncoselectivity reflects the increased availability
of the CRE for binding cellular transcription factors that
upregulate P4 selectively in transformed cells. This model is
supported by the relative fitness of no-cre, which is slightly
weakened in A9, but dramatically impaired in 324 K. However,
attempts to further enhance oncoselectivity by reducing the
spacing between PIF half-sites to three, in 3-between, created
a virus with impaired fitness in both A9 and 324 K. Thus,
3-between, with even less affinity for PIF than 4-between,
may have such significantly impaired DNA replication that
the deficit cannot be overcome by enhanced P4 activity, even
in 324 K. This possibility is currently being addressed by
careful comparison of DNA replication and gene expression
between mutant and wildtype viruses in one-step growth
conditions in normal and transformed cell pairs.
The in vitro cell model employed here, of relatively normal,
but immortal, A9 cells versus highly transformed 324 K cells,
allows us to compare the effect on fitness of the new P4 mutants
with those previously characterized in the same cell pair
(Burnett and Tattersall, 2003). However, this model is not
necessarily representative of fundamental differences between
normal and tumor cells. For instance, the “normal” A9 cells are
of murine origin, whereas the transformed 324 K cells are
human. While one can predict that the expression of SV40
large and small T antigens in 324 K cells likely disrupts the
normal functions of p53, Rb and protein phosphatase 2A, the
extent to which these are normal in A9 cells has not been
rigorously established. However, it should be noted that A9
cells were used by Harris and colleagues (1969) as the
“normal” partner in a series of classic experiments in which
they were fused to each of three cancer cell lines, resulting in
suppression of the tumorigenic phenotype. In order to address
this question more rationally, we are currently developing a
182 J. Paglino et al. / Virology 361 (2007) 174–184model of parvoviral oncoselectivity in stepwise-transformed
human primary fibroblasts (Hahn and Weinberg, 2002), which
we anticipate will allow changes in viral growth parameters to
be related more directly to specific steps in the oncogenic
process.
Materials and methods
Degenerate oligonucleotide selection analysis of the viral CRE
Recombinant human placental CREB-327 protein was
expressed from a baculovirus vector (Chen et al., 1991) and
purified as reported previously (Christensen et al., 1997a).
Selection experiments were performed, as described by Burnett
et al. (2001), using oligonucleotide P1, 5′-TGACAGTTCT-
GACCAAGGNNNCGNNNNNNNNNNNNNCCAGGTACC-
TATAGTTGGf, where underlined sequences represent binding
sites for forward Primer-1, 5′-TGACAGTTCTGACCAAGG-
3′, and reverse Primer-2, 5′-CCAACTATAGGTACCTGG-3′,
respectively. A double-stranded degenerate oligonucleotide
pool was generated by annealing Primer-2 to the degenerate
oligonucleotide and extending with Sequenase (USB Corpora-
tion, Cleveland, Ohio). This oligonucleotide pool was
sequenced directly to confirm that the desired degeneracy
pattern had been achieved. For the preferred site determination,
1 μg (28 pmol) of double-stranded P1 oligonucleotide was
bound by 50 fmol of purified CREB protein and then subjected
to electrophoretic mobility shift assay (EMSA). Following
elution from the gel, recovered probe was amplified in a 50-μl
PCR reaction using Primer-1 and Primer-2. Potential hetero-
duplexes were eliminated by adding 10 μl of fresh reaction mix
plus primers and performing one final round of PCR.
Subsequent rounds of selection were performed exactly as the
first except that 10 μl (0.5 μg–1 μg of DNA) from the PCR
reaction was used as the new oligonucleotide pool. After four
rounds of selection, the oligonucleotide pool was cloned
directly into pCRII (Invitrogen, Carlsbad, CA) and transformed
into the Sure™ strain of E. coli (Stratagene, La Jolla, CA).
Inserts from individual colonies were sequenced with the
33P-labeled Terminator Cycle Sequencing Kit, also obtained
from USB Corporation, using the −40 M13 forward primer.
Cell lines and viruses
A9ouabR11 cells are a mouse L-cell derivative, and 324 K cells
are a simian virus 40 (SV40)-transformed newborn human
kidney fibroblast cell line. All cell types were grown in Dul-
becco's modified Eagle's medium supplemented with 5% fetal
calf serum, as reported previously (Tattersall and Bratton, 1983).
MVMp wildtype virus stocks were generated by transfection of
the infectious clone pdBMVp, as described elsewhere (Kestler et
al., 1999). Stocks of the previously described mutant viruses 4-
between and no-cre and an additional mutant, 3-between, were
generated by ligating synthetic hairpin oligonucleotides, con-
taining each mutation, to the large BsaI fragment of pCHOPII, a
plasmid containing a left-end-truncated version of the MVMp
genome, as reported elsewhere (Burnett and Tattersall, 2003).Cloning of mutant left-hand telomeres from replicative forms
The plasmid pCATCH was designed to remove the internal
BsaAI from pdBMVp, an infectious clone of MVMp containing
the left-hand end in extended form (Kestler et al., 1999), leaving
the single BsaAI site in the left-end palindrome as unique
within the plasmid. For this, pdBMVp was digested with BsrGI
and HpaI, the overhangs filled in with Sequenase (USB Corp.,
Cleveland, Ohio), and the 4,698 basepair fragment then gel
purified and re-circularized. Replicative forms (RF) of left-end
mutant viruses 3-between, 4-between and no-cre were isolated
from infected A9 cells by a modified Hirt procedure (Tattersall
et al., 1973). Monomer RF was gel purified and digested with
BsrGI and BsaAI. The 1,223 basepair fragment was gel purified
and cloned into pCATCH, verified by sequencing and converted
to full-length infectious clones by restoring to each the BsrGI to
XbaI fragment from pdBMVp.
Direct engineering of left-hand telomeric mutations
A new recipient plasmid for synthetic left-hand telomeres,
pCLIP-distal, was generated using two primers with 5′ terminal
“outward facing” SapI sites (lower case), 5′-gaagagcAAAGG-
CAAGCGTAAAGGC-3′, and 5′-gaagagcTGATTGAATCGC-
GAGTGG-3′, which were designed to amplify a 1.4-kb region
from the bacteriophage ΦX174 genome. The ΦX174-derived
PCR product was rendered blunt with Klenow fragment,
phosphorylated with T4 polynucleotide kinase and cloned into
the 4.6-kb fragment of pCATCH that had been pre-cleaved with
BsaAI and PmeI. pCLIP distal was then derived by restoring, to
this construct, the BsrGI–XbaI fragment of pdBMVp. The
ΦX174 fragment within this construct can readily be removed
with SapI, leaving non-complementary overhangs, within
authentic MVM sequence, that facilitate directional cloning of
substitute hairpin sequences.
To generate the mutant clone pdBMVp-symmetric-CRE,
the following oligonucleotides were synthesized and annealed
to each other: 5′-gttTAAACTCCCTGAACCGCTTA-
TCATTTTTAGAACTGACCAACCATGTGAAACG-
TAAGTGACGTCTGACTGCCGAAGGCAGCGCG-
CGCAGCGCGCGTCATGACGTCACTTACG-3′ and
5′-tcaCGTAAGTGACGTCATGACGCGCGCTGCGCG-
CGCTGCCTTCGGCAGTCAGACGTCACTTACGTTT-
CACATGGTTGGTCAGTTCTAAAAATGATAAGCGGTT-
CAGGGAGTTTA-3′, where lower case indicates the 5′
overhangs complementary to those generated by SapI in the
recipient plasmid, and the mutated bases are underlined. The
resulting double-stranded oligonucleotide was cloned into
pCLIP pre-cleaved with SapI, and the product verified by
DNA sequencing.
Recovery of virus from infectious plasmids and generation of
purified viral stocks
A9 cells were seeded at 5×105 per 60-mm-diameter dish and
transfectedwith 2 μg of infectious plasmid DNAusing Superfect
(Qiagen, Valencia, CA). Cells were subcultured 1:6 the next day
183J. Paglino et al. / Virology 361 (2007) 174–184and harvested 3 days later, when they showed conspicuous
cytopathic effects from the virus. Cell pellets were resuspended
in 50 mM Tris–HCl, 0.5 mM EDTA, pH 8.7 (TE8.7), virus was
liberated by freezing and thawing three times and residual cell
debris was removed by centrifugation. Virions were purified by
centrifugation through an iodixanol (Optiprep, Axis-Shield,
Oslo, Norway) density step gradient (15% in 1 mLTE8.7, 35%
in 2 mL TE8.7, 45% in 2 mL phosphate-buffered saline (PBS)
and 55% in 1 mL PBS) at 35,000 rpm for 18 h at 18 °C in a
Beckman SW41 rotor, and subsequently stored at 4 °C. The
genome concentration of stocks was measured by digestion with
micrococcal nuclease followed by addition of EDTA to 0.2 M,
protease K digestion and addition of SDS to 0.5%. Following
electrophoresis through a denaturing alkaline agarose gel,
Southern transfer and hybridization with a 32P-labeled genomic
probe, viral genomes were quantitated using a Molecular
Dynamics PhosphorImager SI.
Infection initiation assay
A9 or 324 K cells were seeded at 2,500 cells per 6-mm-
diameter spot on Teflon-coated “spot slides” (Cell-Line
Associates, Inc., Newfield, NJ) and infected the next day with
purified virus in 15 μl of medium containing 1% fetal bovine
serum and 10mMHEPES, pH 7.3, at 37 °C for 2 h. Inocula were
then replaced with 50 μl medium containing Clostridium per-
fringens neuraminidase (Sigma, St. Louis, MO) at 0.1mg/mL, to
destroy MVM receptor, thus preventing released virus from
reentering cells (Cotmore and Tattersall, 1987). After fixation at
24 h post-infection in 2.5% paraformaldehyde, cells were
stained with monoclonal murine antibody against NS1, and
primary antibodies were detected with Texas-Red conjugated
goat anti-mouse IgG (Jackson ImmunoResearch Laboratories,
West Grove, PA).
Differential real-time quantitative PCR
Primers and probes for Q-PCR were designed using Primer
Express® software and employed TaqMan® technology (Applied
Biosystems, Foster City, CA). As described in the text, the ‘variant’
wildtype virus incorporates silent mutations that allow it to bind the
fluorescent probe 5′-VIC-TAGGTTCCAGTAGCGAACT-
CATCGCCA-TAMRA-3′, while each of the ‘standard’ viruses
bind the fluorescent probe 5′-FAM-TAAGTGCCTGTGG-
CAAATTCGTCCCCT-TAMRA-3′. Fluorescent probes were
purchased from Applied Biosystems. PCR amplification was
accomplished with primers GF-UP-TAQ 5′-CACAACAAATCA-
CATTGCTCAGAA-3′ and GF-DOWN-TAQ 5′-TTGC-
CACGTGTGTGTGAGTTT-3′, each at 9 μM. PCR reactions
were performed and analyzed using the Applied Biosystems
PRISM® 7700 Sequence Detection System instrument and soft-
ware, in accordance with the manufacturer's recommendations.
Competition in co-culture
A9 or 324 K cells were seeded at 5×105 per dish in 100-mm-
diameter dishes and infected with an equimolar mixture of the‘variant’ wildtype with ‘standard’ versions of wildtype,
3-between, 4-between, symmetric-CRE or no-cre, as described
in the text, to give a total multiplicity of 40 genomes per cell.
Cells were harvested at 48 h post-infection, virus extracted by
three freeze–thaw cycles, residual cell debris was removed by
centrifugation and virus extracts were stored at −20 °C.
‘Standard’ and ‘variant’ genome concentrations were assayed
by differential real-time quantitative PCR.
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